Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit-Reference-Cited by-同舟云学术

Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit

Published:2017-02-20 Issue:4 Volume:23 Page:528-537
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Garmann D.¹,McLeay S.²,Shah A.³,Vis P.⁴,Maas Enriquez M.¹,Ploeger B.A.⁵

Affiliation:

1. Bayer AG; Wuppertal Germany

2. Model Answers Pty Ltd; Brisbane Qld Australia

3. Bayer; Whippany NJ USA

4. LAP&P Consultants BV; Leiden The Netherlands

5. Bayer AG; Berlin Germany

Funder

Bayer

Bayer HealthCare

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hae.13192/fullpdf

Reference21 articles.

1. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A;Collins;J Thromb Haemost,2009

2. International Prophylaxis Study Group, Pharmacokinetics Expert Working Group. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia;Collins;Haemophilia,2011

3. Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A;Bjorkman;Haemophilia,2010

4. Project on Factor VIII/Factor IX Pharmacokinetics of the Factor VIII/Factor IX Scientific and Standardization Committee of the ISTH. Measurement of factor VIII pharmacokinetics in routine clinical practice;Bjorkman;J Thromb Haemost,2013

5. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight;Bjorkman;Blood,2012

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive performance of pharmacokinetic-guided prophylactic dosing of factor concentrates in hemophilia A and B;Research and Practice in Thrombosis and Haemostasis;2024-03

2. Development and internal validation of a clinical prediction model for individualized dosing of BAY 81-8973, A full-length recombinant factor VIII, in pediatric patients with haemophilia A;Thrombosis Research;2023-12

3. “A personalized limited sampling approach to better estimate terminal half‐life of FVIII concentrates”: Comment from Huang et al.;Journal of Thrombosis and Haemostasis;2022-10

4. Dosing for Personalized Prophylaxis in Hemophilia A Highly Varies on the Underlying Population Pharmacokinetic Models;Therapeutic Drug Monitoring;2022-10

5. Enhanced pharmacokinetics and reduced bleeds in boys with hemophilia A after switching to Kovaltry from other standard half‐life factor VIII concentrates;Research and Practice in Thrombosis and Haemostasis;2022-02